LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy

被引：23

作者：

Motzer, Robert J. ^{[1
]}

Schmidinger, Manuela ^{[2
]}

Eto, Masatoshi ^{[3
]}

Suarez, Cristina ^{[4
]}

Figlin, Robert ^{[5
]}

Liu, Yanfang ^{[6
]}

Perini, Rodolfo ^{[6
]}

Zhang, Yayan ^{[6
]}

Heng, Daniel Y. C. ^{[7
]}

机构：

[1] Memorial Sloan Kettering Canc Ctr, New York, NY 10065 USA

[2] Med Univ Vienna, A-1090 Vienna, Austria

[3] Kyushu Univ Hosp, Fukuoka 8128582, Japan

[4] Vall dHebron Univ Hosp, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona 08035, Spain

[5] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[6] Merck & Co Inc, Rahway, NJ 07065 USA

[7] Tom Baker Canc Clin, Calgary, AB T2N 4N2, Canada

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 02期

关键词：

clear cell renal cell carcinoma; HIF-2 alpha inhibitor; immune checkpoint inhibitor; metastatic; PD-1/PD-L1; inhibitor; OPEN-LABEL; EVEROLIMUS; SUNITINIB; TRIAL; PEMBROLIZUMAB; NIVOLUMAB; AXITINIB;

D O I：

10.2217/fon-2022-0802

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The first-in-class, small molecule HIF-2 alpha inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2 alpha also regulates VEGF expression and is involved in resistance to anti-VEGF therapy. This study describes the rationale and design for a randomized, phase III study evaluating efficacy and safety of belzutifan plus the tyrosine kinase inhibitor (TKI) lenvatinib versus the TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second-line setting or as adjuvant therapy. Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile.

引用

页码：113 / 121

页数：9

共 34 条

[1]

[Anonymous], 2020, LENV LENV CAPS OR US

[2] Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment [J].

Capozzi, Monica ;

De Divitiis, Chiara ;

Ottaiano, Alessandro ;

von Arx, Claudia ;

Scala, Stefania ;

Tatangelo, Fabiana ;

Delrio, Paolo ;

Tafuto, Salvatore .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :3847-3860

[3] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[4]

Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]

[5] Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis [J].

Choueiri, Toni K. ;

Bauer, Todd M. ;

Papadopoulos, Kyriakos P. ;

Plimack, Elizabeth R. ;

Merchan, Jaime R. ;

McDermott, David F. ;

Michaelson, M. Dror ;

Appleman, Leonard J. ;

Thamake, Sanjay ;

Perini, Rodolfo F. ;

Zojwalla, Naseem J. ;

Jonasch, Eric .

NATURE MEDICINE, 2021, 27 (05) :802-+

[6] Targeting the HIF2-VEGF axis in renal cell carcinoma [J].

Choueiri, Toni K. ;

Kaelin, William G., Jr. .

NATURE MEDICINE, 2020, 26 (10) :1519-1530

[7] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[8] Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma [J].

Courtney, Kevin D. ;

Infante, Jeffrey R. ;

Lam, Elaine T. ;

Figlin, Robert A. ;

Rini, Brian I. ;

Brugarolas, James ;

Zojwalla, Naseem J. ;

Lowe, Ann M. ;

Wang, Keshi ;

Wallace, Eli M. ;

Josey, John A. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :867-+

[9] Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor [J].

Dai, Zhiyu ;

Zhu, Maggie M. ;

Peng, Yi ;

Machireddy, Narsa ;

Evans, Colin E. ;

Machado, Roberto ;

Zhang, Xianming ;

Zhao, You-Yang .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (11) :1423-1434

[10] Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma [J].

Delea, T. E. ;

Khuu, A. ;

Heng, D. Y. C. ;

Haas, T. ;

Soulieres, D. .

BRITISH JOURNAL OF CANCER, 2012, 107 (07) :1059-1068

← 1 2 3 4 →